Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.34 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.34 |
| ▸ | ADRA2C known ✓ | P18825 | 3/20 | 0.34 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.32 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.32 |
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.31 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1670260 | 1.00 | ADRA2A (0.34) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D | |
| SCHEMBL1669608 | 0.90 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D | |
| Fumaric Acid SCHEMBL1672613 | 0.80 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D | |
| Fumaric Acid SCHEMBL1672611 | 0.80 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D | |
| SCHEMBL1670261 | 0.72 | SMN1; SMN2 (0.33) | ADRA2AADRA2BADRA2CALDH1A1RAB9A | |
| Fumaric Acid SCHEMBL1672620 | 0.69 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D | |
| Fumaric Acid SCHEMBL1672617 | 0.69 | ADRA2A (0.49) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D | |
| Fumaric Acid SCHEMBL1669795 | 0.67 | KDM4E (0.46) | ADRA2AADRA2BADRA2CALDH1A1RAB9A | |
| Fumaric Acid SCHEMBL1669798 | 0.67 | KDM4E (0.46) | ADRA2AADRA2BADRA2CALDH1A1RAB9A | |
| SCHEMBL7202913 | 0.67 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CALDH1A1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | claimed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | claimed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | claimed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | claimed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | claimed |
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9522150-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ALLERGAN, INC. | 2015-07-30 | — | — | US | disclosed |
| US-9040532-B2 | Alpha adrenergic receptor modulators | ALLERGAN, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2486009-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | Allergan, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044229-A1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209351-A1 | Alpha Adrenergic Receptor Modulators | ADRB1, ADRB2, ADRA2C | ADRA2A 5/4885ADRA2B 9/4885ADRA2C 3/4885 |
| US-20120208821-A1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ADRB1, ADRB2, ADRA2C | ADRA2A 5/4885ADRA2B 9/4885ADRA2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.